Herfarth, Hans (2002) Colorectal cancer: Risk and prevention in inflammatory bowel diseases. CHIRURGISCHE GASTROENTEROLOGIE, 18 (4). pp. 319-324. ISSN 0177-9990
Full text not available from this repository. (Request a copy)Abstract
The increased risk of colorectal cancer represents a significant problem in the clinical management of patients with long-standing ulcerative colitis or Crohn's disease with a predominant manifestation in the colon. Risk factors for the development of colorectal cancer in patients with these chronic inflammatory bowel diseases are a disease duration of at least 8-10 years, extensive disease (pancolitis) and the presence of the concomitant hepatobiliary complication, primary sclerosing cholangitis. Numerous epidemiologic studies provide strong evidence that sustained use of aspirin and other traditional nonsteroidal anti-inflammatory drugs (NSAIDs), which inhibit the cyclo-oxygenase-1 and -2 isoenzymes, may reduce the risk of colon cancer. Data from several retrospective analyses of patients with ulcerative colitis, which will be depicted in the following review, also suggest a potential chemopreventive role of sulfasalazine or 5-aminosalicylic acid.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | PRIMARY SCLEROSING CHOLANGITIS; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; EXTENSIVE ULCERATIVE-COLITIS; COLON-CANCER; URSODEOXYCHOLIC ACID; CYCLOOXYGENASE-2 INHIBITOR; PROSTAGLANDIN E(2); CROHNS-DISEASE; REDUCED RISK; F344 RATS; ulcerative colitis; Crohn's disease; colorectal cancer; chemoprevention |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Innere Medizin I |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 28 Sep 2021 10:04 |
| Last Modified: | 28 Sep 2021 10:04 |
| URI: | https://pred.uni-regensburg.de/id/eprint/39594 |
Actions (login required)
 |
View Item |
